|
Age (years)
|
63 ± 11
|
|
Male sex
|
271 (69)
|
|
Race
|
|
White
|
292 (74.5)
|
|
Black
|
93 (23.7)
|
|
Asian
|
3 (0.8)
|
|
Other or not reported
|
4 (1.0)
|
|
Past medical history
|
|
Stroke or TIA
|
48 (12.2)
|
|
Gastrointestinal hemorrhage
|
7 (1.8)
|
|
Intracranial hemorrhage
|
2 (0.5)
|
|
PCI indication
|
|
STEMI
|
74 (18.9)
|
|
NSTEMI
|
99 (25.2)
|
|
Unstable angina
|
174 (44.4)
|
|
Stable coronary disease
|
45 (11.5)
|
|
P2Y12 inhibitor on admission
|
|
Clopidogrel
|
99 (25.3)
|
|
Prasugrel
|
9 (2.3)
|
|
Ticagrelor
|
13 (3.3)
|
|
Other or not available
|
11 (2.8)
|
|
Anticoagulant on admissiona
|
|
Warfarin
|
9 (2.3)
|
|
Direct oral anticoagulant
|
12 (3.0)
|
|
Low molecular weight heparin
|
1 (0.3)
|
|
Not available
|
9 (2.3)
|
|
Anticoagulant at dischargea
|
|
Warfarin
|
16 (4.1)
|
|
Direct oral anticoagulant
|
16 (4.1)
|
|
Low molecular weight heparin
|
1 (0.3)
|
|
CYP2C19 phenotype
|
|
Poor metabolizer (*2/*2)
|
7 (1.8)
|
|
Intermediate metabolizer (*1/*2, *2/*17)
|
106 (27.0)
|
|
Normal metabolizer (*1/*1)
|
145 (37.0)
|
|
Rapid metabolizer (*1/*17)
|
110 (28.1)
|
|
Ultra-rapid metabolizer (*17/*17)
|
20 (5.1)
|
|
Inconclusive
|
4 (1.0)
|
